What's Happening?
Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for MYQORZO® (aficamten). This approval updates the drug's U.S. prescribing information to include data from
the MAPLE-HCM Phase 3 trial. The trial compared the efficacy of MYQORZO to metoprolol, a standard-of-care beta-blocker, in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). MYQORZO demonstrated superior improvements in exercise capacity, symptoms, and cardiac biomarkers compared to metoprolol. This makes MYQORZO the only cardiac myosin inhibitor with comparative effectiveness data against a beta-blocker in its U.S. label. The drug, initially approved in December 2025 based on the SEQUOIA-HCM trial, is also approved in China, the European Union, the United Kingdom, and Canada. MYQORZO carries a Boxed Warning due to the risk of heart failure and is available only through a restricted Risk Evaluation and Mitigation Strategy (REMS) program, requiring careful monitoring of left ventricular ejection fraction (LVEF) before and during treatment.
Why It's Important?
This FDA approval is significant for the treatment of obstructive hypertrophic cardiomyopathy (oHCM) in the U.S., as it provides cardiologists and patients with crucial comparative data. For decades, beta-blockers like metoprolol have been a primary treatment for oHCM without extensive comparative clinical trials. The inclusion of MAPLE-HCM trial data in MYQORZO's label offers a new benchmark, potentially shifting treatment paradigms and informing more evidence-based decisions. Patients with oHCM, a condition that limits the heart's pumping function and reduces exercise capacity, stand to benefit from a treatment that has demonstrated superior improvements in key health indicators. The Boxed Warning and REMS program highlight the serious nature of potential side effects, particularly heart failure due to systolic dysfunction, underscoring the need for stringent patient monitoring and management. This development could lead to improved quality of life and functional capacity for a subset of the approximately one in 350 individuals worldwide affected by HCM.
What's Next?
Following this label update, healthcare providers in the U.S. will have enhanced information to guide their prescribing decisions for MYQORZO in patients with symptomatic oHCM. The MYQORZO REMS Program will continue to ensure that the drug is prescribed and dispensed under controlled conditions, with ongoing echocardiogram assessments to monitor for systolic dysfunction. Cytokinetics plans to submit a Supplemental New Drug Application in Q4 2026 for aficamten in patients with non-obstructive HCM (nHCM), based on positive results from the ACACIA-HCM trial. This indicates a broader strategy to expand the drug's indications and reach more patients with different forms of HCM. Further clinical investigations, such as CEDAR-HCM in a pediatric population and FOREST-HCM as an open-label extension study, are also underway, suggesting potential future approvals for new patient demographics and long-term safety and efficacy data.
Beyond the Headlines
The approval of MYQORZO with comparative data against a long-standing standard-of-care drug like metoprolol represents a broader shift in pharmaceutical development and regulatory expectations. It emphasizes the increasing demand for head-to-head clinical trials that provide clear evidence of superiority or non-inferiority, moving beyond comparisons to placebo. This trend benefits patients by offering more informed treatment choices and pushing pharmaceutical companies to develop truly innovative therapies. The stringent REMS program and Boxed Warning also highlight the FDA's commitment to patient safety, particularly for drugs with significant potential side effects. This balance between efficacy and safety is a constant challenge in drug development, and MYQORZO's case illustrates the complex regulatory landscape. Furthermore, the global approvals of MYQORZO in multiple countries underscore the international nature of drug development and the potential for new treatments to impact patient care worldwide, while also navigating diverse regulatory environments.













